Gaucher's disease in Albanian children: Casuistics and Treatment

Iranian Journal of Pediatrics

Volumn 21, Issue 1, 2011, Pages 1-7

  Shehi, Behar ^a   Boçari, Gëzim ^a   Vyshka, Gentian ^a   Xhepa, Rezar ^a   Alushani, Dritan ^a  

^a UNIVERSITY HOSPITAL CENTER MOTHER TERESA   (Albania)

Author keywords

Cerebrosides; Ceredase; Cerezyme; Enzyme replacement therapy; Gaucher disease; Glucocerebrosidase

Indexed keywords

BIOLOGICAL MARKER; CHITOTRIOSIDASE; IMIGLUCERASE;

ADOLESCENT; ADULT; ALBANIA; ARTICLE; CHILD; CLINICAL ARTICLE; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEMOGLOBIN DETERMINATION; HEPATOMEGALY; HUMAN; MALE; PATIENT MONITORING; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 79952910524     PISSN: 10184406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brady OR. Introduction: overview and historical perspective in Gaucher disease. In: Futerman AH, Zimran A, eds. Gaucher Disease Boca Raton, Fla, CRC/Taylor & Francis. 2007; Pp: 1-13.
2. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351(19):1972-1977.
3. Parenti G, Sebastio G, Andria G. Malattie metaboliche. In: Cao A, Dalla Piccola B, Notarangelo LD, (eds). Malattie genetiche. Molecole e geni. Diagnosi, prevenzione e terapia Piccin-Nuova: Libraria. 2004; Pp:53-76.
4. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008;29(5):567-583.
5. Raphael S, Ashok V. Neuronopathic Gaucher disease. In: Futerman AH, Zimran A, (eds). Gaucher Disease Boca Raton, Fl: CRC Press, Taylor & Francis. 2007; Pp: 175-196.
6. Zammarchi E, Donati MA, Morrone A. Errori congeniti del metabolismo. In: Neri G, Maurizio G. eds. Genetica Umana e Medica Elsevier: Masson. 2007; Pp: 185-200.
7. Futerman AH. Cellular pathology in Gaucher disease. In: Futerman AH, Zimran A, eds. Gaucher Disease Boca Raton, Fl: CRC Press, Taylor & Francis. 2007; Pp: 97-108.
8. Gregory P, Noel W, Hans A. Therapeutic goals in the treatment of Gaucher's disease. Semin Hematol 2004;41(4):4-14.
9. Zidar BL, Hartsock RJ, Lee RE, et al. Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. Am J Clin Pathol 1987; 87(4):533-536.
10. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144(1):112-120.
11. Dreborg S, Erikson A, Hagberg B. Gaucher disease -norrbottnian type. Eur J Pediatr 1980;133(2): 107-118.
12. Dahl N, Wadelius C, Anneren G, et al. Mutation analysis for prenatal diagnosis and heterozygote detection of Gaucher disease type 3 (norrbottnian type). Prena Diagn 1992;12(7): 603-608.
13. Gaucher Registry© 2010, Ref nr: CZ/29/P090/0-05/10. Available at: http://www.gaucherregistry.com. Access date: Sept 10th, 2010.
14. Kraoua I, Sedel F, Caillaud C, et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain and Development. Brain Dev 2010;33(2):131-139.
15. Sibille A, Eng CM, Kim SJ, et al. Phenotype/genotype correlations in Gaucher disease type I: Clinical and therapeutic implications. Am J Hum Genet 1993; 52(6):1094-1101.
16. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163(2):67-75.
17. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005;35(2): 259-267.
18. Diaz GA, Gelb BD, Risch N, et al. Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations. Am J Hum Genet 2000; 66(6):1821-1832.
19. Germain DP, Benistan K. Prenatal diagnosis of Gaucher disease. Rev Med Intern 2007;28(Suppl 2): S193-S197
20. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372(9645):1263-1271.
21. Mario M, Erik A. Imaging in Gaucher disease, focusing on bone pathology. In: Futerman AH, Zimran A, eds. Gaucher Disease Boca Raton, Fl: CRC Press, Taylor & Francis. 2007; Pp:269-286.
22. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113(2):112-119.
23. The Belgian Working Group on Gaucher Disease. Guidelines for diagnosis, treatment and monitoring of Gaucher's disease. June 2004. Available at: www.lysomed.be/practical/documents/Gaucher%20 guidelines_final.pdf Access date: Sep 18th, 2010.
24. Bembi B, Agosti E, Zanatta M, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet 1994;344(8938):1679-1682.
25. Whitfield PD, Nelson P, Sharp PC, et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 2002;75(1):46-55.